Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Willingness of children and adolescents to have a COVID-19 vaccination: results of a large whole schools survey in England

FAZEL M. et al, (2021), E Clinical Medicine

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

Flaxman A. et al, (2021), Lancet, 398, 981 - 990

Impact of Vaccination on Haemophilus influenzae Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal.

Shrestha S. et al, (2021), J Infect Dis, 224, S267 - S274

Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus.

Lin G-L. et al, (2021), Nat Commun, 12

A Bayesian approach for estimating typhoid fever incidence from large-scale facility-based passive surveillance data.

Phillips MT. et al, (2021), Stat Med

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.

Madhi SA. et al, (2021), Lancet HIV

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021), Nat Commun, 12

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021), Nature communications, 12, 5061 - 5061

Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial.

Qadri F. et al, (2021), Lancet

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.

Frater J. et al, (2021), Lancet HIV, 8, e474 - e485

Sustained T Cell Immunity, Protection and Boosting Using Extended Dosing Intervals of BNT162b2 mRNA Vaccine

Payne R. et al, (2021)

Persistence of Immunity Following 2-Dose Priming with a 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks or 6 and 14 Weeks of Age in Nepalese Toddlers.

Gurung M. et al, (2021), Pediatr Infect Dis J

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil; an exploratory analysis of a randomised controlled trial

Clemens SC. et al, (2021)

"Should children be offered covid-19 vaccination?" No

Wilkinson D. et al, (2021), BMJ: British Medical Journal

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Flaxman A. et al, (2021), SSRN Electronic Journal

A Salmonella Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination.

Jones E. et al, (2021), Microorganisms, 9

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Feng S. et al, (2021)

Divergent trajectories of antiviral memory after SARS-Cov-2 infection

Tomic* A. et al, (2021)

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply.

Voysey M. and Pollard AJ., (2021), Lancet, 397

Injection fears and COVID-19 vaccine hesitancy

FREEMAN D., (2021), Psychological Medicine

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?